LH-RH Agonists in Oncology

1. Front Matter

   Pages I-XIX

   PDF

2. Mechanisms of Action

   1. Front Matter

      Pages 1-1

      PDF

   2. Gonadotropin-Releasing Hormone: Physiological and Endocrinological Aspects

      • D. Klingmüller, H. U. Schweikert

      Pages 3-9

   3. Preclinical Studies on Suppression of Follicular Maturation and Oestrogen Secretion in Rats and Monkeys

      • J. Sandow, H. M. Fraser, K. Engelbart, H. Seidel, H. Donaubauer, W. von Rechenberg

      Pages 10-21

   4. Direct Antitumor Effects of an LH-RH Agonist

      • J. A. Foekens, J. G. M. Klijn

      Pages 22-29

3. Prostatic Cancer

   1. Front Matter

      Pages 31-31

      PDF

   2. Comments on the Management of Metastatic Prostatic Cancer With LH-RH Analogues

      • F. H. Schröder

      Pages 33-40

   3. Results of the Treatment of Locally Advanced Prostatic Carcinoma with LH-RH Analogues

      • R. Nagel, H. Al-Abadi, V. Borgmann

      Pages 41-59

   4. Combination Therapy with Flutamide and Castration (Orchiectomy or LH-RH Agonist) in Untreated Patients with Advanced Prostate Cancer

      • A. Dupont, F. Labrie, M. Giguère, J. P. Borsanyi, Y. Lacourciere, A. Bélanger et al.

      Pages 60-71

   5. LH-RH Analogues for Palliation of Advanced Prostatic Carcinoma. A Critical Review After Five Years of Experience

      • G. H. Jacobi, U. K. Wenderoth, H. v. Wallenberg, M. Gatto, R. Hohenfellner

      Pages 72-88

4. Protection of Spermatogenesis

   1. Front Matter

      Pages 89-89

      PDF

   2. Reversibility of GnRH Agonist-Induced Inhibition of Testicular Function: Comparison Between Rat, Monkey and Man

      • G. F. Weinbauer, E. Nieschlag

      Pages 91-104

   3. Use of Buserelin for the Protection of Spermatogenesis in Cytotoxic Treatment

      • W. Krause

      Pages 105-110

   4. Reproductive and Endocrine Gonadal Capacity with and without GnRH Analogue Application During Chemotherapy in Patients Treated for Testicular Cancer

      • E.-D. Kreuser, W. D. Hetzel

      Pages 111-119

   5. Prevention of Infertility from Chemotherapy by Administration of a Long-Acting Preparation of D-Trp-6-Luteinizing Hormone-Releasing Hormone? A Report on Two Cases

      • D. Klingmüller, N. Niederle, L. Heuser, H. U. Schweikert

      Pages 120-127

5. Breast Cancer

   1. Front Matter

      Pages 129-129

      PDF

   2. Clinical Trials of the LH-RH Analogue Leuprolide in Human Breast Cancer

      • H. A. Harvey, A. Lipton, D. T. Max

      Pages 131-138

   3. LH-RH Agonists in the Treatment of Metastatic Breast Cancer: Five Years Experience

      • J. G. M. Klijn

      Pages 139-148

   4. Buserelin in the Treatment of Premenopausal Patients with Advanced Breast Cancer

      • K. Höffken, R. Becher, E. Kurschel, C. Doberauer, C. U. Anders, R. Callies et al.

      Pages 149-163

   5. Treatment of Postmenopausal Women with Breast Cancer with Gonadotropin-Releasing Hormone Analogues

      • J. Waxman

      Pages 164-167

Hormonal treatment of malignant diseases came of age quite some years ago. Nevertheless, developments in this field are still progressing at a steady pace. During recent years, the detection of new endocrine feedback loops and the availability of new classes of hormonal agents made it possible to predictively interfere with hor­ mone actions. Besides the intellectual challenge of modulating the hormone system, there is an important new aspect associated with recent research on hormones and cancer: new developments have generally led to a reduction in treatment-induced morbidity. As aromataseinhibitors are substituted for adrenalectomy, controlled interference with the hypothalamic-gonadotrophic axis is likely to replace surgical removal of the relevant glands, i. e. , the pituitary gland or the gonads. With the detection of the luteinizing hormone releasing hormone (LH-RH), its structural analysis, and the synthesis of analogs of this decapeptide hormone, a tool became available not only for treatment of sterility or endometriosis but also for switching off gonadal activity in a reversible manner. Evidence has accumulated over the past few years that LH-RH agonists can serve as "medical orchiectomy" in prostate cancer. As a logical consequence, hypogonadotropic gonadal insufficiency induced by LH-RH agonists was investigated in patients with breast cancer. Of equal importance were the attempts to prevent infertility from cytostatic drugs by temporar­ ily suspending gonadal function.

• Gonadotropin
• cancer
• carcinoma
• chemotherapy
• clinical trial
• fertility
• hormone
• hormones
• infertility
• oncology
• prevention
• prostate cancer
• spermatogenesis

• Innere Klinik und Poliklinik Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen 1, Federal Republic of Germany

  Klaus Höffken

Policies and ethics